Today’s Stock Alert: Nektar Therapeutics Can’t Burn Your Short Portfolio. Has Another Weak Session

Today's Stock Alert: Nektar Therapeutics Can't Burn Your Short Portfolio. Has Another Weak Session

The stock of Nektar Therapeutics (NASDAQ:NKTR) is a huge mover today! The stock decreased 3.33% or $0.48 during the last trading session, hitting $13.93. About 1.40M shares traded hands. Nektar Therapeutics (NASDAQ:NKTR) has declined 5.63% since April 13, 2016 and is downtrending. It has underperformed by 9.56% the S&P500.
The move comes after 6 months negative chart setup for the $2.13B company. It was reported on Nov, 15 by Barchart.com. We have $12.82 PT which if reached, will make NASDAQ:NKTR worth $170.40M less.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Out of 3 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Nektar Therapeutics has been the topic of 5 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Aegis Capital on Tuesday, November 8. TheStreet downgraded the shares of NKTR in a report on Wednesday, August 26 to “Hold” rating. The rating was maintained by Roth Capital with “Buy” on Monday, September 21. As per Thursday, January 7, the company rating was maintained by Piper Jaffray.

According to Zacks Investment Research, “Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company’s wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.”

Insitutional Activity: The institutional sentiment increased to 1.14 in Q2 2016. Its up 0.05, from 1.09 in 2016Q1. The ratio improved, as 16 funds sold all Nektar Therapeutics shares owned while 56 reduced positions. 22 funds bought stakes while 60 increased positions. They now own 131.60 million shares or 3.23% less from 135.99 million shares in 2016Q1.
Credit Suisse Ag last reported 0.01% of its portfolio in the stock. Artisan Partnership has invested 0.03% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Northern Trust Corporation last reported 0.01% of its portfolio in the stock. Rothschild Asset last reported 28,596 shares in the company. Moreover, Fmr Ltd Llc has 0% invested in Nektar Therapeutics (NASDAQ:NKTR) for 1.38 million shares. Profund Advsrs Lc accumulated 0.01% or 17,625 shares. Barclays Public Limited Liability, a United Kingdom-based fund reported 11,324 shares. Bnp Paribas Arbitrage Sa accumulated 80,962 shares or 0.01% of the stock. Savings Bank Of Montreal Can holds 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 6,187 shares. Swiss Commercial Bank, a Switzerland-based fund reported 223,100 shares. Moreover, Franklin Street Advsr Inc Nc has 0.28% invested in Nektar Therapeutics (NASDAQ:NKTR) for 105,500 shares. Ra Cap Llc has 6.35% invested in the company for 3.22 million shares. Public Sector Pension Invest Board, a Quebec – Canada-based fund reported 96,500 shares. Teachers holds 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 302,617 shares. Advisory Svcs Network Ltd has 400 shares for 0% of their US portfolio.

Insider Transactions: Since May 16, 2016, the stock had 1 insider buy, and 16 selling transactions for $5.64 million net activity. $171,540 worth of shares were sold by Lingnau Lutz on Thursday, September 15. The insider Hora Maninder sold 3,305 shares worth $58,036. CHESS ROBERT sold 5,000 shares worth $86,300. 3,305 shares were sold by Labrucherie Gil M, worth $58,036. Gergel Ivan P. sold $5,867 worth of stock or 432 shares. The insider Thomsen Jillian B. sold $69,731. ROBIN HOWARD W sold $1.56M worth of stock or 87,500 shares.

More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Cnbc.com which released: “Nektar Therapeutics shares fall on secondary stock offering” on October 19, 2016, also Prnewswire.com with their article: “Nektar Therapeutics Announces Upcoming Presentations at the 2016 Society for …” published on October 28, 2016, Fool.com published: “Why WW Grainger, Badger Meter, and Nektar Therapeutics Slumped Today” on October 18, 2016. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: Prnewswire.com and their article: “Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose …” published on November 09, 2016 as well as Prnewswire.com‘s news article titled: “Nektar Therapeutics to Present at Jefferies 2016 Global Healthcare Conference …” with publication date: November 14, 2016.

NKTR Company Profile

Nektar Therapeutics, incorporated on June 3, 1998, is a clinical-stage biopharmaceutical company. The Firm is developing a pipeline of drug candidates that utilizes its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of molecular entities that targets known mechanisms of action. The Company’s pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives and immunology. The Company’s research and development activities involve small molecule drugs, peptides and other biologic drug candidates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment